Beyond Psychotropic: Potential Repurposing of Fluoxetine toward Cancer Therapy
International Journal of Molecular Sciences · 07.06.2024 · 25 (12) · 6314
DOI: 10.3390/ijms25126314 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.06.2024. Verfasst von Sultan F Kadasah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Faculty of Science, University of Bisha, P.O. Box 551, Bisha 61922, Saudi Arabia. Hauptthemen laut MEDLINE: Drug Repositioning, Fluoxetine. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Drug repurposing, rebranding an existing drug for a new therapeutic indication, is deemed a beneficial approach for a quick and cost-effective drug discovery process by skipping preclinical, Phase 1 trials and pharmacokinetic studies. Several psychotropic drugs, including selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), were studied for their potential application in different diseases, especially in cancer therapy. Fluoxetine (FLX) is one of the most prescribed psychotropic agents from the SSRIs class for the treatment of several neuropsychiatric disorders with a favorable safety profile. FLX exhibited different oncolytic effects via mechanisms distinct from its main serotonergic activity. Taking advantage of its ability to rapidly penetrate the blood–brain barrier, FLX could be particularly useful in brain tumors. This was proved by different in vitro and in vivo experiments using FLX as a monotherapy or combination with temozolomide (TMZ) or radiotherapy. In this review of the literature, we summarize the potential pleiotropic oncolytic roles of FLX against different cancers, highlighting the multifaceted activities of FLX and its ability to interrupt cancer proliferation via several molecular mechanisms and even surmount multidrug resistance (MDR). We elaborated on the successful synergistic combinations such as FXR/temozolomide and FXR/raloxifene for the treatment of glioblastoma and breast cancer, respectively. We showcased beneficial pharmaceutical trials to load FLX onto carriers to enhance its safety and efficacy on cancer cells. This is the first review article extensively summarizing all previous FLX repurposing studies for the management of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Faculty of Science, University of Bisha, P.O. Box 551, Bisha 61922, Saudi Arabia.
- Department of Pharmacology, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia.
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
ORCID-Profile: Sultan F Kadasah, Abdulaziz M S Alqahtani, Mohamed O Radwan
Zitieren
APA
Kadasah, S. F., Alqahtani, A. M. S., Alkhammash, A., & Radwan, M. O. (2024). Beyond Psychotropic: Potential Repurposing of Fluoxetine toward Cancer Therapy. International Journal of Molecular Sciences, 25(12), 6314. https://doi.org/10.3390/ijms25126314
Vancouver
Kadasah SF, Alqahtani AMS, Alkhammash A, Radwan MO. Beyond Psychotropic: Potential Repurposing of Fluoxetine toward Cancer Therapy. International Journal of Molecular Sciences. 2024;25(12):6314. doi:10.3390/ijms25126314
BibTeX
@article{Kadasah2024,
author = {Kadasah, Sultan F and Alqahtani, Abdulaziz M S and Alkhammash, Abdullah and Radwan, Mohamed O},
title = {Beyond Psychotropic: Potential Repurposing of Fluoxetine toward Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {12},
pages = {6314},
doi = {10.3390/ijms25126314}
}
EUVIMED